4.5 Article

Cascade reaction-mediated efficient ferroptosis synergizes with immunomodulation for high-performance cancer therapy

Journal

BIOMATERIALS SCIENCE
Volume 8, Issue 22, Pages 6272-6285

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d0bm01168a

Keywords

-

Ask authors/readers for more resources

Given that traditional anticancer therapies fail to significantly improve the prognoses, new modalities with high efficiency are urgently needed. Herein, a nanozyme-based formulation, which synergized efficient ferroptosis with immunomodulation for high-performance cancer therapy, was constructed. Specifically, ultrasmall CaO2 and Fe3O4 nanoparticles (NPs) were co-loaded onto dendritic mesoporous silica nanoparticles (DMSN) followed by coating with the pH-responsive membrane, which could not only prevent the leakage of the cargos but also realize tumor-specific release. After intravenous injection, the H+ ions in a weak acidic microenvironment triggered the cascade reaction by reacting with CaO2 and produced abundant H2O2 in the tumor tissue. Subsequently, the produced H2O2 was catalyzed into toxic hydroxyl radicals (x2d9;OH) through a Fenton-like reaction mediated by Fe3O4 NPs and induced ferroptosis, which promoted the release of tumor-associated antigens and generated an immunogenic tumor microenvironment (TME). Furthermore, immunomodulation was achieved by the polarization of tumor-associated macrophages (TAMs) induced by pH changes. The efficient ferroptosis and immunomodulation cooperatively paved the way for the inhibition of tumors. Beyond the inhibition of the primary tumor, the formulation could also efficiently provoke the immune response to exert a potent anticancer effect through combining with an immune checkpoint blockade. After being co-loaded with aCD47, the phagocytes could be stimulated and enhance the uptake efficiency of the tumor antigens to realize efficient immunotherapy with few abnormalities. Our approach thus offers a versatile formulation to realize the synergism of ferroptosis and immunomodulation/immunotherapy for high-performance cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available